Endometrial cancer+1
Not recruitingStudy of Retifanlimab Alone and in Combination with Drug Therapy for Adults with Advanced or Metastatic Endometrial Cancer Who Have Not Responded to Platinum Chemotherapy
Study of Retifanlimab Alone and in Combination with Drug Therapy for Adults with Advanced or Metastatic Endometrial Cancer Who Have Not Responded to Platinum Chemotherapy
- Disease:Endometrial cancerEndometrial cancer metastatic
- Substances:PemigatinibRetifanlimab+2
France- Participants:18–64 years · 65+ years
- Substances:Pemigatinib
- Sponsor:Incyte Corp.











